Eloxx Pharmaceuticals, Inc.
ELOX
$16.57
$0.402.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.61M | 2.14M | 684.00K | 2.00M | 3.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.45M | 3.80M | 1.58M | 5.48M | 6.03M |
| Operating Income | -4.45M | -3.80M | -1.58M | -5.48M | -6.03M |
| Income Before Tax | -4.50M | -3.75M | -1.89M | -6.23M | -6.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.50M | -3.75M | -1.89M | -6.23M | -6.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.50M | -3.75M | -1.89M | -6.23M | -6.32M |
| EBIT | -4.45M | -3.80M | -1.58M | -5.48M | -6.03M |
| EBITDA | -- | -- | -1.57M | -5.47M | -6.02M |
| EPS Basic | -0.66 | -0.93 | -5.45 | -2.88 | -2.92 |
| Normalized Basic EPS | -0.41 | -0.59 | -3.41 | -1.68 | -1.82 |
| EPS Diluted | -0.66 | -0.93 | -5.45 | -2.88 | -2.92 |
| Normalized Diluted EPS | -0.41 | -0.59 | -3.41 | -1.68 | -1.82 |
| Average Basic Shares Outstanding | 6.79M | 52.59M | 347.00K | 2.17M | 2.17M |
| Average Diluted Shares Outstanding | 6.79M | 52.59M | 347.00K | 2.17M | 2.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |